GLP1R and metabolic dysfunction-associated steatotic liver disease: Glucagon-like peptide-1 receptor agonists activate fatty acid oxidation and reduce lipogenesis by modulating lipid transport, AMP-activated protein kinase (AMPK), β-oxidation, and insulin signaling, which have been suggested as critical mechanisms of the pathogenesis of NAFLD/NASH [35,36,37].